ArticleThrombosis journal2025
Efficacy of hyperbaric oxygen combined with dual antiplatelet therapy in elderly patients with acute cerebral infarction and its impact on nerve factors.
Article in Thrombosis journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hyperbaric Oxygen Therapy for Cognitive Impairment Resulting from Neurological Disorders: Mechanisms of Action and Application Advances.International journal of medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to ascertain the efficacy of hyperbaric oxygen therapy (HBOT) combined with dual antiplatelet therapy (DAPT) in elderly patients with acute cerebral infarction (ACI) and its impact on nerve factors.
methodsA total of 122 patients were randomly assigned (1:1) to either the observation group or the control group. Patients in the control group received DAPT, And those in the observation group received HBOT combined with DAPT. Treatment was administered in 3 consecutive daily sessions starting from the date of admission. All patients were evaluated for efficacy after treatment. Before and after treatment, the National Institutes of Health Stroke Scale (NIHSS), and the Chinese Stroke Scale (CSS) were assessed; the levels of serum neuron-specific enolase (NSE) and plasma β-amyloid-42 (Aβ-42), hemorheology indices (whole blood viscosity and plasma viscosity), coagulation indicators [activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), and fibrinogen (Fbg)], and inflammatory factor [matrix metalloproteinase-9 (MMP-9), interleukin-6 (IL-6), and C-reactive protein (CRP)] were measured; the Barthel Index (BI) scores were recorded.
resultsAfter treatment, the observation group exhibited higher total effective rate, longer APTT, PT and TT, and higher BI score compared to the control group (all P < 0.05), while lower NIHSS, CSS scores, lower levels of NSE, Aβ-42, and Fbg, lower whole blood viscosity, plasma viscosity, MMP-9, IL-6 and CRP compared to the control group (all P < 0.05).
conclusionHBOT combined with DAPT can enhance efficacy, ameliorate neurologic impairments, enhance the effect of thrombolysis, reduce inflammatory response, and improve activities of daily living in elderly patients with ACI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.